Day One

• Using a SWOT analysis approach, what are the strengths, weaknesses, opportunities and threats of bispecifics/ multispecifics compared to other drug modalities?
• In which cases are bispecifics/multispecifics being prioritized for autoimmune and immunology versus oncology?
• What datapoints are being assessed when it comes to bispecifics/multispecifics from a data package perspective for approval and backing from pharma?
• What data is lacking across the board for bispecifics/multispecifics?
• How are novel versus derisked targets being assessed, and what weighting/value is placed on safety and efficacy data, versus other data points?
• What stimulates interest around bispecific/multispecific assets versus platform technologies that generate target, construct and format menus?

• B7-H7 is broadly upregulated across multiple high-prevalence malignancies with significant unmet need, while maintaining a restricted and favorable expression profile in healthy tissue
• NextPoint lead T-cell engager, NPX372, features an optimized molecular architecture specifically designed to achieve an expansive therapeutic index
• Leveraging a biomarker-driven patient selection strategy and validated preclinical safety data, a streamlined Phase I clinical program has been launched

• Bi- and Tri-specific matrix screening rapidly identifies optimal antibody pairings
• B-Body bispecific and T-Body trispecific antibodies exhibited good killing from in vitro ADC assays across a diverse set of breast cancer cell lines
• Multi-target ADCs demonstrate broader and more durable tumor control in vivo, including in drug-resistant cell populations that evade monospecific therapy

• Highlighting differentiated target identification for first-in-class multispecific drugs
• Benchmarking to known approved TCE drugs
• Leveraging dual targeting to expand therapeutic window and patient prevalence

This structured networking session provides the perfect opportunity to connect with industry frontrunners and key opinion leaders working at the cutting-edge of bispecific, multispecific and immune cell engager innovation. Establish meaningful connections to build upon at the rest of the conference.

• Engineered for Speed: Generate bispecifics from parental IgGs without altering the light chains
• True Plug-and-Play: Easily transition from simple monoclonal antibodies to complex bispecifics
• Fast-Tracked Production: Scale to high-titer, high-quality, stable CHO cell line production in weeks

• Exploring gamma delta T cells as a differentiated immune effector population to overcome limitations associated with classical CD3-based T-cell engagers
• Solving the scarcity issue: Novel TCE design or mechanism to expand gamma-delta T-cells in vivo
• Leveraging preclinical evidence and clinical insight from gamma delta T-cell therapies to inform safety, efficacy, and broader applicability

• Xilio is deploying its clinically validated masking technology to advance several highly differentiated bi- and multispecific molecules towards clinical development
• XTX501, Xilio’s PD1/masked IL-2 bispecific has the potential to be a foundational backbone therapy for combination regimens across a broad range of solid tumors, and the program is on track to advance into the clinic this year
• XTX601, Xilio’s masked CLDN18.2 T-cell engager and Xilio’s masked PSMA+STEAP1 dual-TAA targeted T-cell engager with co-stimulation both have firstin- class potential and further demonstrate the power of our masking technology to unlock the potential of T-cell engagers

Private Lunch (Invite Only) with Hosting Partner – MindWalk: A Complete Biointelligence Ecosystem to Empower VHH Discovery with a Function First Approach

• Biparatopic antibodies, which engage two non-overlapping epitopes on a single target, offer distinct mechanistic advantages including enhanced avidity, receptor clustering, and resistance mitigation, but conventional discovery approaches often struggle to generate pairs that are both functionally optimized and readily manufacturable
• Alloy Therapeutics has developed the ATX-CLC transgenic mouse platform, a suite of common light chain mice that enable monoclonal antibodies to be mixed and matched across a range of bispecific formats while preserving native Fab architecture, and the mAbForge Multi high-throughput screening workflow for rapid pairing and functional triage
• Together, these platforms support the discovery of fully manufacturable biparatopic and bispecific candidates, including T-cell engager formats, without compromising binding affinity or developability
• We highlight a biparatopic case study spanning discovery through format selection, demonstrating how our platforms accelerate development of next-generation multispecific biologics across diverse therapeutic areas

• EvolveImmune Therapeutics is pioneering next generation multispecific CD3-T-cell engagers (TcEs) with integrated CD2 costimulation, to optimize T-cell fitness for deeper and more durable patient benefits
• The EVOLVE platform provides superior T-cell activation, proliferation and tumor cell killing compared to first generation bispecific CD3-TcEs, without excess cytokine release or tonic T-cell activation
• EVOLVE104 is a trispecific TcE that binds to the UL Binding Proteins 2/5/6 (ULBP2/5/6) on tumor cells and both CD3 and CD2 on T-cells. EVOLVE104 demonstrates a promising preclinical profile, including enhanced T-cell activation and killing of ULBP2/5/6-positive tumor cells compared to first generation bispecific CD3-TcEs. No safety concerns were identified in nonclinical toxicity studies
• EVOLVE104 is currently being evaluated in a first-in-human Phase 1a/1b trial with advanced urothelial carcinomas and squamous cell carcinomas (NCT07217171). Study objectives include assessing the safety, efficacy, pharmacokinetics and pharmacodynamics of EVOLVE104 and identifying the recommended phase 2 dose (RP2D)

• End-to-end antibody solution: Powered by the Harbour Mice® platform for fully human antibodies, Nona Biosciences offers an “Idea-to-Clinic” solution spanning discovery, engineering, and binder optimization
• HBICE® engager platform: Combines this expertise with an off-the-shelf library of TAA and effector arms to deliver transformative bispecific and multispecific immune cell engagers
• Next-generation formats: The small size, flexibility, and modularity of HCAbs enable advanced engagers – biparatopic, mRNA-delivered RiboHBICE®, conditionally active, TCR-mimics (TCRm), and myeloid cell engagers

Connect with peers in a relaxed atmosphere and continue to forge new and existing relationships while exploring the latest advancements in bispecific and multispecific discovery, design and developability. To register your poster submission, please contact info@hansonwade.com

• Conditional CD3 activation via hidden CD3 binder in TROY-Ig scaffold mitigates cytokine release
• CD2 costimulation and CD58 adhesion lowers the threshold for CD3 activation in T-cells
• CD2 costimulation and conditional CD3 activation TROY-Ig scaffold enables increased anti-tumor efficacy in solid tumor microenvironment

• Advanced antibody discovery platforms for biology-driven lead identification
• Comprehensive in vitro functional assays across T-cell engagers (TCEs), immune checkpoint inhibitors, and autoimmune diseases
• Extensive in vivo efficacy models and well-established PK/PD/Tox platforms delivering time- and cost-effective solutions

• Developing a suite of CD28 agonistic antibodies optimized for bispecific engineering to target solid tumors
• Addressing the limited translation of transformative outcomes of T-cell engagers in hematologic cancers, into solid tumors
• Integrating CD28 costimulation into bispecific therapeutics to enhance T-cell effector function and drive robust anti-tumor responses in the solid tumor setting